SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)--Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced the formation of its scientific advisory board. The advisory board will provide strategic oversight on scientific advancements, trends in autoimmunity and Treg cell biology, new technologies, and the company’s preclinical pipeline.
Members of the Scientific Advisory Board include:
Alexander Rudensky, Ph.D., is Chair of the immunology program at the Sloan Kettering Institute and co-founder of Sonoma Biotherapeutics.
Qizhi Tang, Ph.D., is a Professor of Surgery and Director of the Transplantation Research Laboratory at the University of California, San Francisco; and co-founder of Sonoma Biotherapeutics.
Joseph R. Arron, M.D., Ph.D., is Chief Scientific Officer at 23andMe.
Daniel J. Campbell, Ph.D., is Director of the Center for Fundamental Immunology at Benaroya Research Institute and Affiliate Professor, Department of Immunology at University of Washington School of Medicine.
Yvonne Y. Chen, Ph.D., is an Associate Professor, Microbiology, Immunology & Molecular Genetics at University of California, Los Angeles.
Dan Littman, M.D., Ph.D., is a Howard Hughes Medical Institute Investigator, a Helen L. and Martin S. Kimmel Professor of Molecular Immunology, and a Professor of Cell Biology and Pathology at the New York University School of Medicine.
“We have assembled a world-class group of advisors to guide our research efforts,” said Fred Ramsdell, Ph.D., co-founder and Chief Scientific Officer at Sonoma Biotherapeutics, and Chair of the Scientific Advisory Board. “I look forward to working with them as we discover and develop Treg cell therapies designed to restore long-term balance to the immune system."
About Sonoma Biotherapeutics
Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted and durable Treg cell therapies. Sonoma Biotherapeutics is based in South San Francisco and Seattle. For more information visit sonomabio.com and follow on Twitter and LinkedIn.
